ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 271 filers reported holding ACCELERON PHARMA INC in Q2 2021. The put-call ratio across all filers is 1.70 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $214,335,000 | +36.8% | 1,245,412 | -0.2% | 0.36% | +56.7% |
Q2 2021 | $156,628,000 | -32.9% | 1,248,131 | -27.5% | 0.23% | -33.4% |
Q1 2021 | $233,484,000 | +6.2% | 1,721,731 | +0.2% | 0.35% | -3.1% |
Q4 2020 | $219,855,000 | +20.2% | 1,718,421 | +5.7% | 0.36% | +5.6% |
Q3 2020 | $182,929,000 | +28.0% | 1,625,606 | +8.3% | 0.34% | -6.4% |
Q2 2020 | $142,963,000 | +15.4% | 1,500,606 | +8.9% | 0.36% | -31.6% |
Q1 2020 | $123,836,000 | +304.1% | 1,377,950 | +138.4% | 0.53% | +364.0% |
Q4 2019 | $30,643,000 | -17.8% | 577,950 | -38.8% | 0.11% | -13.0% |
Q3 2019 | $37,295,000 | -3.8% | 943,950 | 0.0% | 0.13% | -14.9% |
Q2 2019 | $38,778,000 | -1.3% | 943,950 | +11.8% | 0.15% | -21.4% |
Q1 2019 | $39,303,000 | +141.3% | 843,950 | +125.7% | 0.20% | +84.9% |
Q4 2018 | $16,286,000 | +4.5% | 373,950 | +37.3% | 0.11% | +43.2% |
Q3 2018 | $15,585,000 | – | 272,329 | – | 0.07% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Darwin Global Management, Ltd. | 1,505,012 | $204,095,000 | 39.96% |
Foresite Capital Management III, LLC | 108,630 | $14,731,000 | 12.94% |
Avoro Capital Advisors LLC | 3,000,000 | $406,830,000 | 7.03% |
Octagon Capital Advisors LP | 112,363 | $15,238,000 | 5.74% |
Artal Group S.A. | 1,400,000 | $189,854,000 | 3.36% |
Eversept Partners, LP | 241,981 | $32,815,043 | 2.47% |
NWI MANAGEMENT LP | 200,000 | $27,122,000 | 2.26% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 60,500 | $8,199,000 | 2.17% |
Affinity Asset Advisors, LLC | 45,000 | $6,102,000 | 2.07% |
Parkman Healthcare Partners LLC | 62,780 | $8,514,000 | 1.98% |